Sc Pharmaceuticals Inc. SCPH
We take great care to ensure that the data presented and summarized in this overview for scPharmaceuticals Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SCPH
View all-
Orbimed Advisors LLC San Diego, CA6.06MShares$14.4 Million0.58% of portfolio
-
Rubric Capital Management LP New York, NY4.78MShares$11.4 Million0.28% of portfolio
-
Aigh Capital Management LLC Baltimore, MD4.17MShares$9.93 Million5.98% of portfolio
-
King Luther Capital Management Corp Fort Worth, TX2.86MShares$6.8 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.11MShares$5.02 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.91MShares$4.55 Million0.0% of portfolio
-
Suvretta Capital Management, LLC New York, NY1.84MShares$4.38 Million0.27% of portfolio
-
Black Rock Inc. New York, NY1.77MShares$4.21 Million0.0% of portfolio
-
J. Goldman & CO LP New York, NY1.22MShares$2.9 Million0.12% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA1.2MShares$2.86 Million1.89% of portfolio
Latest Institutional Activity in SCPH
Top Purchases
Top Sells
About SCPH
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
Insider Transactions at SCPH
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Feb 11
2025
|
John H Tucker President and CEO |
SELL
Grant, award, or other acquisition
|
Direct |
200,000
-31.21%
|
-
|
|
Feb 11
2025
|
Rachael Nokes CFO and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
88,445
+36.17%
|
-
|
|
Jan 03
2025
|
John H Tucker President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
13,360
-5.26%
|
$40,080
$3.56 P/Share
|
|
Jan 03
2025
|
Rachael Nokes CFO and Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,235
-7.19%
|
$15,705
$3.56 P/Share
|
|
Aug 26
2024
|
Leonard D Schaeffer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,347
+9.93%
|
$22,694
$2.52 P/Share
|
|
Aug 13
2024
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
500,000
+7.75%
|
$2,000,000
$4.0 P/Share
|
|
Aug 06
2024
|
Rachael Nokes CFO and Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,445
+12.54%
|
-
|
|
Jan 18
2024
|
John H Tucker President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
113,560
+30.88%
|
-
|
|
Jan 18
2024
|
Rachael Nokes CFO and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
41,840
+40.14%
|
-
|
|
Jan 02
2024
|
Rachael Nokes CFO and Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,027
-4.76%
|
$6,162
$6.39 P/Share
|
|
Jan 02
2024
|
John H Tucker President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,942
-3.39%
|
$29,652
$6.39 P/Share
|
|
Jan 19
2023
|
Rachael Nokes CFO and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
11,700
+35.14%
|
$70,200
$6.14 P/Share
|
|
Jan 19
2023
|
John H Tucker President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
66,665
+31.41%
|
$399,990
$6.14 P/Share
|
|
Nov 25
2022
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
762,380
+12.52%
|
$3,811,900
$5.25 P/Share
|
|
Oct 10
2022
|
5 Am Partners Iv, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
562,466
-17.15%
|
$2,249,864
$4.09 P/Share
|
|
Oct 07
2022
|
John H Tucker President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,288
-11.53%
|
$41,152
$4.98 P/Share
|
|
Oct 07
2022
|
John H Tucker President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
42,250
+32.14%
|
-
|
|
Oct 06
2022
|
5 Am Partners Iv, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
37,534
-1.13%
|
$187,670
$5.02 P/Share
|
|
Sep 07
2022
|
5 Am Partners Iv, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
200,000
-5.66%
|
$800,000
$4.75 P/Share
|
|
Sep 06
2022
|
5 Am Partners Iv, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
26,622
-0.75%
|
$133,110
$5.52 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 500K shares |
|---|---|
| Grant, award, or other acquisition | 88.4K shares |
| Exercise of conversion of derivative security | 21.8K shares |
| Grant, award, or other acquisition | 200K shares |
|---|---|
| Payment of exercise price or tax liability | 18.6K shares |